Background Endothelin-1 is involved in chronic pulmonary hypertension.
Its role in acute pulmonary hypertension due to hypoxia in humans is
not clear. We therefore studied the influence of hypoxia caused by exp
osure to high altitude on plasma endothelin-1 levels, arterial blood g
ases, and pulmonary arterial pressure in subjects taking nifedipine or
placebo. Methods and Results Twenty-two healthy volunteers were inves
tigated at low altitude (490 m) and high altitude (4559 m). Arterial b
lood gases were analyzed immediately, endothelin-1 was measured by rad
ioimmunoassay, and pulmonary artery pressure was assessed by Doppler e
chocardiography. After baseline investigations, the mountaineers were
allocated in a randomized double-blind fashion to receive either place
bo or nifedipine (20 mg TID) during rapid ascent to high altitude with
in 22 hours. Tests were repeated at the high-altitude research laborat
ories located in the Capanna ''Regina Margherita'' (Italy, 4559 m). Pl
asma endothelin-1 was increased twofold at high altitude (5.9+/-2.2 pg
/mL compared with 2.9+/-1.1 pg/mL, P<.05), was inversely related to ar
terial PO2 (r=-.46, P<.001), and correlated with pulmonary artery pres
sure (r=.52, P<.002). At high altitude, arterial endothelin-1 was lowe
r (4.3+/-1.6 pg/mL) than venous endothelin-1 (5.9+/-2.2 pg/mL, P<.001)
, indicating either predominant production in the venous vasculature o
r pronounced clearance in the pulmonary circulation. The calcium antag
onist nifedipine, which lowered pulmonary artery pressure at high alti
tude (32+/-5 versus 42+/-11 mm Hg, P<.05), had no influence on plasma
endothelin-1 levels. The administration of 35% O-2 at high altitude no
rmalized arterial PO2, tended to decrease endothelin-1, and decreased
pulmonary artery pressure accordingly. Conclusions We conclude that pl
asma endothelin-1 is increased at high altitude, but whether or not it
represents an important pathogenetic factor for pulmonary hypertensio
n remains to be investigated.